ALS / Motor Neurone Disease
A wet-lab-ready drug pairing for ALS
The Challenge
The Euan MacDonald Centre for Motor Neurone Disease Research at the University of Edinburgh, led by Dr Bhuvaneish Selvaraj, asked Novamine to identify pairs of drugs, drawn from libraries of compounds already studied or approved in humans, most likely to reverse the cellular damage behind the great majority of ALS cases. Constraints were strict: both drugs had to reach the brain at safe human doses, carry no overlapping serious side effects, and act through complementary biological routes. The output had to be a ranked shortlist a wet lab could actually run.
The Leap Novamine Made
Rather than treating the failing motor neuron as a single broken part to be fixed, the engine utilised closed-loop control principles to reframe the cell as a system trapped in a self-reinforcing feedback cycle; where any single intervention is quietly undone by the other half of the loop within hours. This led to a pairing strategy, largely absent from the repurposing literature, in which one drug restores the cell's internal organisation while the other removes the stress that would push it straight back into failure. Neither alone produces a durable result. Together they produce a rescue that holds.
Value to the Client
The output is a wet-lab-ready protocol that narrows thousands of compounds to a specific, defensible pair, complete with controls, timing, and pass/fail criteria. It compresses months of exploratory screening into a single targeted experiment, and carries clinical translation potential because both drugs already have human safety data. The pairing has been selected for funded laboratory trials at the Euan MacDonald Centre, now underway.
“
The Novamine system offers exciting potential not only to identify novel treatment targets and strategies, but also potential multi-drug/gene therapy approaches, where the therapeutic whole will be greater than the sum of the parts.
Chief Scientist, Motor Neurone Disease Association